Abstract:Background: Essential tremor (ET) is one of the most common movement disorders. Treatment is based primarily on pharmacological agents. On this basis, although primidone and propranolol are well-established treatments in clinical practice, they could be ineffective in 25% to 55% of patients and can produce serious adverse events (AEs) in a large percentage of individuals. For these reasons, evaluating treatment alternatives for ET may be a worthwhile pursuit. Alprazolam has been suggested as a potentially useful agent for treatment of individuals with ET, but its efficacy and safety are uncertain. Objectives: PrimaryTo assess the efficacy and safety of alprazolam in the treatment of individuals with ET. SecondaryTo examine effects of alprazolam treatment on the quality of life of people with ET. Search methods: We carried out a systematic search without language restrictions to identify all relevant trials. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 1966 to September 2015), EMBASE (January 1988 to September 2015), the National Institute for Health and Care Excellence (NICE) (1999 to September 2015), ClinicalTrials.gov (1997 to September 2015) and the World Health Organiza tion (WHO) International Clinical Trials Registry Platform (ICTRP) (2004 to September 2015). We handsearched grey literature and examined the reference lists of identified studies and reviews. Selection criteria: We included all randomised controlled trials (RCTs) of alprazolam versus placebo or any other treatment. We included studies in which ET was diagnosed according to accepted and validated diagnostic criteria. We excluded studies that included patients presenting with secondary forms of tremor or reporting only neurophysiological parameters for the pur p ose of assessing outcomes. Data collection and analysis: Two review authors independently collected and extracted data using a data collection form. We assessed risk of bias and the body of evidence. We used inverse variance methods for continuous outcomes and measurement scales. We compared differences between treatment groups as mean differences. We used Review Manager software for management and analysis of data. Main results: We included in this review one trial that compared alprazolam versus placebo (24 participants). It was judged to have high overall risk of bias. We graded the overall quality of evidence as very low. Compared with those given placebo, participants treated with alprazolam showed a significant reduction in tremor severity (mean difference (MD) -0.75, 95% confidence interval (CI) -0.83 to -0.67). Nine alprazolam-treated participants (75%) developed AEs, mainly represented by sedation (50%), constipation (17%) and dry mouth (9%). No participants in the alprazolam group and no p articipants in the placebo group discontinued treatment and dropped out of the study. Authors' conclusions: Currently available data reveal evidence insufficient for assessment of the efficacy and safety of alprazolam treatment for individuals with ET.

Risk of Suicide Attempts and Intentional Self-Harm on Alprazolam

Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database

Mother's little helper turned a foe: Alprazolam use, misuse, and abuse

Alprazolam Use Improves Psychological Status and Reduces Hospitalization Costs in Patients with Paroxysmal Supraventricular Tachycardia Underwent Radiofrequency Catheter Ablation

Alprazolam: Pharmacokinetics, Clinical Efficacy, and Mechanism of Action

Prescription medications for insomnia are associated with suicidal thoughts and behaviors in two nationally representative samples

An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database

Benzodiazepine use for anxiety disorders is associated with increased long-term risk of mood and substance use disorders: A large-scale retrospective cohort study

Differential effects of alprazolam against methylphenidate-induced neurobehavioral alterations

Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study

Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014

Drug Treatment for Attention-Deficit/hyperactivity Disorder and Suicidal Behaviour: Register Based Study

Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database

Risk factors of antidepressant treatment emergent suicidal ideas or attempted suicide among patients with bipolar depression

Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial

Driving impairment and altered ocular activity under the effects of alprazolam and alcohol: A randomized, double-blind, placebo-controlled study

Benzodiazepine use and incident risk of sudden cardiac arrest in patients with cardiovascular diseases

Alprazolam for essential tremor

Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-Analysis

Association of Benzodiazepine Treatment for Sleep Disorders With Drug Overdose Risk Among Young People

Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment.